Laboratory and clinical studies on SY5555 for urinary tract infections and prostatitis

Keizo Suzuki; Masaki Horiba; Shinobu Kato; Toshio Fujioka; Koichi Ishiguro; Seiichi Aoki; Yorio Naide; Masanori Yanaoka; Kiyohito Ishikawa; Toshiyuki Tanaka

doi:10.11250/chemotherapy1953.42.Supplement1_445

Laboratory and clinical studies on SY5555 for urinary tract infections and prostatitis

Keizo Suzuki, Masaki Horiba, Shinobu Kato, Toshio Fujioka, Koichi Ishiguro, Seiichi Aoki, Yorio Naide, Masanori Yanaoka, Kiyohito Ishikawa, Toshiyuki Tanaka

Quality and Safety in Healthcare

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

A new oral penem antibiotic, SY5555, was administered in the treatment of urinary tract infection and prostatitis. The drug was given at doses of 300∼600 mg a day for 3∼14 days. The clinical efficacy was evaluated by the Japanese UTI Committee criteria in 44 of 58 patients treated. The efficacy was 100% in 24 cases of acute uncomplicated cystitis, and 60%(9 of 15) in chronic complicated UTI. Among 3 cases of acute bacterial prostatitis caused by Escherichia coli, bacteriological eradication was achieved in only one case. In the safety profile, adverse events were noted in 7 cases (12.5%) including mainly digestive disorders such as diarrhea or loose stool. No abnormal values were detected except for slight elevation of γ-GTP in one case.

Original language	English
Pages (from-to)	445-453
Number of pages	9
Journal	CHEMOTHERAPY
Volume	42
DOIs	https://doi.org/10.11250/chemotherapy1953.42.Supplement1_445
Publication status	Published - 1994

All Science Journal Classification (ASJC) codes

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.42.Supplement1_445

Cite this

@article{2bd295f21be44c71852d84957109a616,

title = "Laboratory and clinical studies on SY5555 for urinary tract infections and prostatitis",

abstract = "A new oral penem antibiotic, SY5555, was administered in the treatment of urinary tract infection and prostatitis. The drug was given at doses of 300∼600 mg a day for 3∼14 days. The clinical efficacy was evaluated by the Japanese UTI Committee criteria in 44 of 58 patients treated. The efficacy was 100% in 24 cases of acute uncomplicated cystitis, and 60%(9 of 15) in chronic complicated UTI. Among 3 cases of acute bacterial prostatitis caused by Escherichia coli, bacteriological eradication was achieved in only one case. In the safety profile, adverse events were noted in 7 cases (12.5%) including mainly digestive disorders such as diarrhea or loose stool. No abnormal values were detected except for slight elevation of γ-GTP in one case.",

author = "Keizo Suzuki and Masaki Horiba and Shinobu Kato and Toshio Fujioka and Koichi Ishiguro and Seiichi Aoki and Yorio Naide and Masanori Yanaoka and Kiyohito Ishikawa and Toshiyuki Tanaka",

year = "1994",

doi = "10.11250/chemotherapy1953.42.Supplement1_445",

language = "English",

volume = "42",

pages = "445--453",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Laboratory and clinical studies on SY5555 for urinary tract infections and prostatitis

AU - Suzuki, Keizo

AU - Horiba, Masaki

AU - Kato, Shinobu

AU - Fujioka, Toshio

AU - Ishiguro, Koichi

AU - Aoki, Seiichi

AU - Naide, Yorio

AU - Yanaoka, Masanori

AU - Ishikawa, Kiyohito

AU - Tanaka, Toshiyuki

PY - 1994

Y1 - 1994

N2 - A new oral penem antibiotic, SY5555, was administered in the treatment of urinary tract infection and prostatitis. The drug was given at doses of 300∼600 mg a day for 3∼14 days. The clinical efficacy was evaluated by the Japanese UTI Committee criteria in 44 of 58 patients treated. The efficacy was 100% in 24 cases of acute uncomplicated cystitis, and 60%(9 of 15) in chronic complicated UTI. Among 3 cases of acute bacterial prostatitis caused by Escherichia coli, bacteriological eradication was achieved in only one case. In the safety profile, adverse events were noted in 7 cases (12.5%) including mainly digestive disorders such as diarrhea or loose stool. No abnormal values were detected except for slight elevation of γ-GTP in one case.

AB - A new oral penem antibiotic, SY5555, was administered in the treatment of urinary tract infection and prostatitis. The drug was given at doses of 300∼600 mg a day for 3∼14 days. The clinical efficacy was evaluated by the Japanese UTI Committee criteria in 44 of 58 patients treated. The efficacy was 100% in 24 cases of acute uncomplicated cystitis, and 60%(9 of 15) in chronic complicated UTI. Among 3 cases of acute bacterial prostatitis caused by Escherichia coli, bacteriological eradication was achieved in only one case. In the safety profile, adverse events were noted in 7 cases (12.5%) including mainly digestive disorders such as diarrhea or loose stool. No abnormal values were detected except for slight elevation of γ-GTP in one case.

UR - http://www.scopus.com/inward/record.url?scp=0028362785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028362785&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.42.Supplement1_445

DO - 10.11250/chemotherapy1953.42.Supplement1_445

M3 - Article

AN - SCOPUS:0028362785

SN - 0009-3165

VL - 42

SP - 445

EP - 453

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Laboratory and clinical studies on SY5555 for urinary tract infections and prostatitis

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this